IFORMULATE
LIVE

Serial Number

90713374

Owner

HTD Biosystems Inc

Attorney

Micah Drayton

First Use Date

Jun 28, 2010

Filing Date

May 15, 2021

Add to watchlist:

No watchlists yet
View on USPTO

IFORMULATE Trademark

Serial Number: 90713374 • Registration: 6743350

IFORMULATE is a trademark filed by HTD Biosystems Inc on May 15, 2021. The trademark is classified under Class 1 (Chemicals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

HTD Biosystems Inc (3 trademarks)

Suite E
PLEASANTON, CA 94566

Entity Type: 03

Trademark Details

Filing Date

May 15, 2021

Registration Date

May 31, 2022

First Use Anywhere

June 28, 2010

First Use in Commerce

June 28, 2010

Published for Opposition

March 15, 2022

Goods & Services

Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of liquid formulations of proteins, antibodies, peptides, and other small molecules, and for use in evaluating their respective solubility properties, all the foregoing using Design of Experiments Approach in a multivariate fashion; Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of nanoparticle formulations, including investigating parameters related to drug release, particle size, aggregations, and drug integrity, all the foregoing using Design of Experiments Approach in a multivariate fashion; Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of vaccine stability formulations, all the foregoing using Design of Experiments Approach in a multivariate fashion; Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of antibody conjugates and antibody drug conjugates (ADCs), all the foregoing using Design of Experiments Approach in a multivariate fashion; Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of diagnostic reagents and for use in evaluating their stability and compatibility in various formulations with respect to the effect of pH, ionic strength, buffer and stability concentrations, all the foregoing using Design of Experiments Approach in a multivariate fashion

Scientific research services related to providing an optimum process for identifying stable formulations for biotech drugs such as protein, peptides, and small molecules, using advanced Design of Experiments strategy; Scientific laboratory services related to providing an optimum process for identifying stable formulations for biotech drugs such as protein, peptides, and small molecules, using advanced Design of Experiments strategy

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 20, 2023 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Apr 20, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 20, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 20, 2023 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 31, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
May 31, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 15, 2022 NPUB
PUBLISHED FOR OPPOSITION
Mar 15, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 23, 2022 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 10, 2022 PREV
ASSIGNED TO LIE
Feb 8, 2022 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 4, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 31, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 31, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 31, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 31, 2022 CNEA
ASSIGNED TO EXAMINER
Jan 25, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 13, 2021 NWOS
NEW APPLICATION ENTERED
May 19, 2021 NWAP